AAO 2024: Long-term low-dose antiviral treatment benefits …
Oct 19, 2024 · Long-term, low-dose antiviral treatment reduces the risk for potentially vision-damaging bouts of inflammation and infection, as well as pain, which occur when shingles …
What your patients need to know about eye color-changing drops
Aug 28, 2024 · The American Academy of Ophthalmology indicates that consumers who may see the eye color-changing drops advertised and used on TikTok or elsewhere online should be …
Ophthalmology Times - Ophthalmology news, articles, and events
Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that …
New canalicular gel shows promise for dry eye treatment
Nov 13, 2024 · Reviewed by Mark Packer, MD; and Eric Donnenfeld, MD. In June 2024, a canalicular gel device (Lacrifill, Nordic Pharma) was introduced to the US market, and a recent …
AAO 2024: Livionex reports positive end-of-phase 2 meeting with …
Oct 18, 2024 · According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, improves vision in patients with early-to …
FDA approves Bausch + Lomb’s enVista Envy range of IOLs
Oct 14, 2024 · Key Takeaways. enVista Envy IOLs provide a continuous range of vision with high dysphotopsia tolerance, enhancing cataract surgery outcomes. U.S. and Canadian trials …
Intense pulsed light for treatment of dry eye disease
Oct 31, 2024 · Joanne F. Shen, MD, director of the dry eye clinic at Mayo Clinic's campus in Phoenix, Arizona, and a research team studied 35 patients treated with IPL/MGX. The team …
ASCRS 2024: What advancements in Light Adjustable Lens …
Apr 10, 2024 · Neda Nikpoor, MD, spoke to Ophthalmology Times about her presentation on the Light Adjustable Lens during an ASCRS symposia on IOL calculations.. Video Transcript. …
Understanding cerebral/cortical visual impairment: New insights …
Nov 22, 2024 · Cerebral/cortical visual impairment (CVI) is a leading cause of childhood blindness, caused by brain damage to visual pathways. Researchers are refining its definition …
LumiThera’s Valeda Light Delivery System receives marketing ...
Nov 6, 2024 · LumiThera Inc. announced the US Food & Drug Administration (FDA) has authorized marketing of Valeda Light Delivery System for the treatment of patients with dry …